Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'oedème maculaire diabétique chronique [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Fiche du document
2015
- doi: 10.1016/j.jfo.2014.09.007
- issn: 0181-5512
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jfo.2014.09.007
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25601517
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1773-0597
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0EDEFD6ACA3B4
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Photocoagulation Jabs (Injections) Shots (Injections) Quantitative analysis Quantitative chemical analysis Causality Effect and cause Cause and effect Final cause Methods of analysis Analysis and chemistry Analytical methods Chemical analysis Analysis methods Analysis and examination Inoculación Causa y efecto Análisis cuantitativo Química analítica cuantitativa Oedème maculaire VEGF Vascular endothelial cell growth factor Essais quantitatifs (chimie) Chimie analytique quantitative Dosage Analyse chimique Dosage Causation Cause finale Cause Principe de causalité Loi de causalité Effet et cause Cause et effet Piqûres (thérapeutique) Infiltrations thérapeutiques Injection Inoculations thérapeutiques Injections thérapeutiquesCiter ce document
G. Soubrane et al., « Micro-implant d'acétonide de fluocinolone (ILUVIEN(®)) pour l'oedème maculaire diabétique chronique [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema]. », Serveur académique Lausannois, ID : 10.1016/j.jfo.2014.09.007
Métriques
Partage / Export
Résumé
Diabetic macular edema (DME) is a frequent complication of diabetic retinopathy and may cause severe visual loss. In this article, we examine the pathophysiology of DME and review various treatment options, such as laser photocoagulation, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and steroids including ILUVIEN(®), which is a new sustained-release, non biodegradable, injectable, intravitreal micro-implant containing fluocinolone acetonide. The results of the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) studies, conducted to evaluate the efficacy and safety of ILUVIEN(®) in DME, are discussed.